Healthcare Industry News: Meloxicam
News Release - July 19, 2006
Par Pharmaceutical Receives Final Approval to Market Meloxicam Tablets
SPRING VALLEY, N.Y., July 19 (HSMN NewsFeed) -- Par Pharmaceutical Companies, Inc. (NYSE: PRX ) today announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Meloxicam tablets, 7.5 mg and 15 mg. Meloxicam is the generic version of Boehringer Ingelheim's Mobic® and is used for the treatment of osteoarthritis. Annual U.S. sales of Mobic® exceed $1 billion. Par will begin shipping the product immediately.Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA filings and approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, uncertainty of patent litigation filed against us, availability of raw materials, the regulatory environment, fluctuations in operating results and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission, such as the Company's Form 10-K, Form 10-Q, and Form 8-K reports.
Source: Par Pharmaceutical Companies
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
